European Medical Solutions (ALEMS.BR)
EUR 4.9
(1.07%)
EUR 4.9
(1.07%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 18.13 Million EUR | 27.51% |
| 2022 | 14.21 Million EUR | 10.58% |
| 2021 | 12.85 Million EUR | 127.39% |
| 2020 | 5.65 Million EUR | 9.53% |
| 2019 | 5.16 Million EUR | 145.16% |
| 2018 | 2.1 Million EUR | 351.93% |
| 2017 | 466 Thousand EUR | 8.12% |
| 2016 | 431 Thousand EUR | -89.82% |
| 2015 | 4.23 Million EUR | 0.0% |
| 2014 | - EUR | -100.0% |
| 2013 | 885 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 16.98 Million EUR | 19.43% |
| 2023 Q4 | 18.13 Million EUR | 6.77% |
| 2023 FY | 18.13 Million EUR | 27.51% |
| 2022 Q4 | 14.21 Million EUR | -6.0% |
| 2022 Q2 | 15.12 Million EUR | 282.57% |
| 2021 Q2 | 5.33 Million EUR | -5.71% |
| 2021 Q4 | 3.95 Million EUR | -25.84% |
| 2020 Q4 | 5.65 Million EUR | 4.8% |
| 2020 Q2 | 5.39 Million EUR | 4.51% |
| 2019 Q2 | 1.29 Million EUR | -38.37% |
| 2019 Q4 | 5.16 Million EUR | 297.77% |
| 2018 Q2 | 484 Thousand EUR | 3.86% |
| 2018 Q4 | 2.1 Million EUR | 335.12% |
| 2017 Q4 | 466 Thousand EUR | 3.79% |
| 2017 Q2 | 449 Thousand EUR | 4.18% |
| 2016 Q2 | - EUR | -100.0% |
| 2016 Q4 | 431 Thousand EUR | 0.0% |
| 2015 Q4 | 4.23 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nicox S.A. | 25.15 Million EUR | 27.917% |
| FERMENTALG | 15.35 Million EUR | -18.086% |
| argenx SE | 18.1 Million EUR | -0.142% |
| BioSenic S.A. | 28.16 Million EUR | 35.617% |
| Celyad Oncology SA | 902 Thousand EUR | -1910.089% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -242.482% |
| Onward Medical N.V. | 16.87 Million EUR | -7.449% |
| Oxurion NV | 12.33 Million EUR | -47.0% |
| PHAXIAM Therapeutics S.A. | 10.19 Million EUR | -77.772% |
| Financière de Tubize SA | 79.2 Million EUR | 77.107% |
| UCB SA | 3.03 Billion EUR | 99.403% |